AnaptysBio (NASDAQ:ANAB) Price Target Raised to $54.00
AnaptysBio (NASDAQ:ANAB – Free Report) had its target price lifted by Guggenheim from $52.00 to $54.00 in a report released on Tuesday morning, MarketBeat.com reports. Guggenheim currently has a buy rating on the biotechnology company’s stock. ANAB has been the subject of several other research reports. Wells Fargo & Company upped their price target on […]
AnaptysBio (NASDAQ:ANAB – Free Report) had its target price lifted by Guggenheim from $52.00 to $54.00 in a report released on Tuesday morning, MarketBeat.com reports. Guggenheim currently has a buy rating on the biotechnology company’s stock. ANAB has been the subject of several other research reports. Wells Fargo & Company upped their price target on […]
